Mannin Research Overview
- Year Founded
-
2012
- Status
-
Acquired/Merged
- Employees
-
6
- Latest Deal Type
-
Later Stage VC
- Investors
-
3
Mannin Research General Information
Description
Developer of biotechnology therapeutics designed to treat ophthalmic diseases through targeted biological mechanisms. The company offers novel drugs targeting the Ang-Tie2 pathway and focused treatment approaches for conditions such as glaucoma, enabling patients with eye disorders to access advanced therapeutic options and improved disease management.
Contact Information
Website
www.mannin.ca(Operating Subsidiary)
Corporate Office
- 1 University Avenue, Floor 3
- Toronto, Ontario M5J 2P1
- Canada
Corporate Office
- 1 University Avenue, Floor 3
- Toronto, Ontario M5J 2P1
- Canada
Mannin Research Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 01-Apr-2024 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 05-Nov-2019 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | 02-Feb-2017 | Completed | Pre-Clinical Trials | |||
| 2. Merger/Acquisition | 13-Jan-2016 | Completed | Pre-Clinical Trials | |||
| 1. Accelerator/Incubator | Completed | Pre-Clinical Trials |
Mannin Research Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Mannin Research Patents
Mannin Research Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021292526-A1 | Small molecule ve-ptp inhibitors | Inactive | 16-Jun-2020 | ||
| EP-4164690-A1 | Small molecule ve-ptp inhibitors | Inactive | 16-Jun-2020 | ||
| CA-3182748-A1 | Ve-ptp inhibitors | Pending | 16-Jun-2020 | ||
| AU-2020432156-A1 | Chimeric fusions between c4-binding protein c-terminal segment and angiopoietin-1 fibrinogen-like domain as angiopoietin mimetics and tie2 agonists to treat vascular diseases | Inactive | 28-Feb-2020 | ||
| CA-3169257-A1 | Chimeric fusions between c4-binding protein c-terminal segment and angiopoietin-1 fibrinogen-like domain as angiopoietin mimetics and tie2 agonists to treat vascular diseases | Pending | 28-Feb-2020 | C07K14/515 |
Mannin Research Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Mannin Research Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Matter (Consulting Services (B2B)) | Accelerator/Incubator |
Mannin Research FAQs
-
When was Mannin Research founded?
Mannin Research was founded in 2012.
-
Where is Mannin Research headquartered?
Mannin Research is headquartered in Toronto, Canada.
-
What is the size of Mannin Research?
Mannin Research has 6 total employees.
-
What industry is Mannin Research in?
Mannin Research’s primary industry is Biotechnology.
-
Is Mannin Research a private or public company?
Mannin Research is a Private company.
-
What is Mannin Research’s current revenue?
The current revenue for Mannin Research is .
-
Who are Mannin Research’s investors?
Matter (Consulting Services (B2B)) has invested in Mannin Research.
-
When was Mannin Research acquired?
Mannin Research was acquired on 01-Apr-2024.
-
Who acquired Mannin Research?
Mannin Research was acquired by Q BioMed.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
